 | • レポートコード：MRC2210A0086 • 出版社/出版日：Transparency Market Research / 2022年7月 • レポート形態：英文、PDF、163ページ • 納品方法：Eメール • 産業分類：医療 |
| Single User | ￥857,660 (USD5,795) | ▷ お問い合わせ |
| Multi User | ￥1,301,660 (USD8,795) | ▷ お問い合わせ |
| Corporate License | ￥1,745,660 (USD11,795) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| Transparency Market Research社の本調査レポートでは、世界の神経膠腫治療市場規模について調査し、序論、仮定・調査手法、エグゼクティブサマリー、市場概要、キーインサイト、種類別（光増感剤治療薬、装置）分析、種類別（低悪性度、高悪性度）分析、治療法別（手術、放射線治療、化学治療、標的薬物治療、その他）分析、地域別（北米、ヨーロッパ、アジア太平洋、中南米、中東/アフリカ）分析、競争状況など、以下の項目を掲載しております。本書では、Bristol-Myers Squibb Company、Genentech,Inc.（F. Hoffmann-La Roche Ltd.、Pfizer,Inc.、Merck＆Co.,Inc、Teva Pharmaceutical Industries Ltd、Sun Pharmaceutical Industries Ltd.、Amgen,Inc.、Other prominent playersなどの企業情報が含まれています。 ・序論 ・仮定・調査手法 ・エグゼクティブサマリー ・市場概要 ・キーインサイト ・世界の神経膠腫治療市場規模：種類別 - 低悪性度神経膠腫治療の市場規模 - 高悪性度神経膠腫治療の市場規模 ・世界の神経膠腫治療市場規模：治療法別 - 神経膠腫用手術の市場規模 - 神経膠腫用放射線治療の市場規模 - 神経膠腫用化学治療の市場規模 - 神経膠腫用標的薬物治療の市場規模 - その他治療法の市場規模 ・世界の神経膠腫治療市場規模：地域別 - 北米の神経膠腫治療市場規模 - ヨーロッパの神経膠腫治療市場規模 - アジア太平洋の神経膠腫治療市場規模 - 中南米の神経膠腫治療市場規模 - 中東/アフリカの神経膠腫治療市場規模 ・競争状況 |
Glioma Treatment Market – Scope of Report
TMR’s report on the global glioma treatment market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2022 to 2031. The report provides revenue of the global glioma treatment market for the period 2017–2031, considering 2021 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global glioma treatment market from 2022 to 2031.
The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players’ product literature, annual reports, press releases, and relevant documents to understand the glioma treatment market.
Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global glioma treatment market.
The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report sheds light on the changing competitive dynamics in the global glioma treatment market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global glioma treatment market.
The report delves into the competitive landscape of the global glioma treatment market. Key players operating in the global glioma treatment market have been identified and each one of these has been profiled, in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are attributes of players in the global glioma treatment market profiled in this report.
RESEARCH METHODOLOGY
The research methodology will be a combination of exhaustive primary and secondary research to analyze the market glioma treatment.
Secondary Research
Secondary research includes a search of company literature, technical writing, patent data, Internet sources, and statistical data from government websites, trade associations, and agencies. This has proven to be the most reliable, effective, and successful approach for obtaining precise data, capturing industry participants’ insights, and recognizing business opportunities.
Secondary research sources that we typically refer, but are not limited to:
Company websites, presentations, annual reports, white papers, technical paper, product brochure
Internal and external proprietary databases and relevant patents
National government documents, statistical databases, and market reports
News articles, press releases, and webcasts specific to companies operating in the market
Specific Secondary Sources:
Industry Sources:
WorldWideScience.org
Elsevier, Inc.
National Institutes of Health (NIH)
PubMed
NCBI
Department of Health Care Service
Trade Data Sources
Trade Map
UN Comtrade
Trade Atlas
Company Information
OneSource Business Browser
Hoover’s
Factiva
Bloomberg
Mergers & Acquisitions
Thomson Mergers & Acquisitions
MergerStat
Profound
Primary Research
During the course of research, we conduct in-depth interviews and discussions with a wide range of key industry participants and opinion leaders. Primary research represents bulk of research efforts, supplemented by extensive secondary research.
We conduct primary interviews on the ongoing basis with industry participants and commentators to validate data and analysis. A typical research interview fulfills the following functions:
Provides first-hand information on market size, market trends, growth trends, competitive landscape, outlook, etc.
Helps in validating and strengthening secondary research findings
Further develops the analysis team’s expertise and market understanding
Primary research involves e-mail interactions, telephonic interviews, as well as face-to-face interviews for each market, category, segment, and sub-segment across geographies
Participants who typically take part in such a process include, but are not limited to:
Industry participants: Marketing/product managers, market intelligence managers, and regional sales managers
Purchasing/Sourcing managers, technical personnel, distributors
Outside experts: Investment bankers, valuation experts, and research analysts specializing in specific markets
Key opinion leaders specializing in different areas corresponding to different industry verticals
List of primary participants, but not limited to:
Advanced Oncotherapy PLC
Danfysik A/S
Hitachi, Ltd.
IBA Worldwide
Mevion Medical Systems, Inc.
Data Triangulation: Information culled from “Secondary & Primary Sources” is cross-checked with “TMR Knowledge Repository”, which is updated every quarter.
Market Estimation: Market size estimations involved in-depth study of product features, technology updates, geographic presence, product demand, sales data (value or volume), historical year-on-year growth, and others. Other approaches were also utilized to derive market size and forecasts. Where no hard data was available, we employed modeling techniques in order to produce comprehensive datasets. A rigorous methodology has been adopted, wherein the available hard data are cross-referenced with the following data types to produce estimates:
Demographic Data: Healthcare expenditure, inflation rates, and others
Industry Indicators: R&D investment, technology stage, and infrastructure, sector growth, and facilities
Market Forecasting: Market forecasts for various segments are derived taking into account drivers, restraints/challenges, and opportunities prevailing in the market and considering advantages/disadvantages of segments/sub-segments over other segments/sub-segments. Business environment, historical sales pattern, unmet needs, competitive intensity, and country-wise surgery data are some of the other pivotal factors, which are considered to derive market forecasts.
レポート目次1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary : Global Glioma Treatment Market
4. Market Overview
4.1. Introduction
4.1.1. Definition
4.1.2. Industry Evolution / Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Glioma Treatment Market Analysis and Forecasts, 2017‒2031
5. Key Insights
5.1. Key Industry Events (Mergers & Acquisitions, Product Launches, Partnerships)
5.2. Pipeline Analysis
5.3. Low Grade Glioma: Overview
5.4. Disease Prevalence Rate & Incidence Rate Globally
5.5. Covid-19 Pandemic Impact on the Industry
6. Global Glioma Treatment Market Analysis and Forecast, by Type
6.1. Introduction & Definition
6.2. Key Findings / Developments
6.3. Market Value Forecast, by Type, 2017‒2031
6.3.1. Low-Grade
6.3.1.1. grade I
6.3.1.2. grade II
6.3.2. High-grade
6.3.2.1. grade III
6.3.2.2. grade IV
6.4. Market Attractiveness, by Type
7. Global Glioma Treatment Market Analysis and Forecast, by Treatment
7.1. Introduction & Definition
7.2. Key Findings / Developments
7.3. Market Value Forecast, by Treatment, 2017‒2031
7.3.1. Surgery
7.3.2. Radiation Therapy
7.3.3. Chemotherapy
7.3.4. Targeted Drug Therapy
7.3.5. Others
7.4. Market Attractiveness, by Treatment
8. Global Glioma Treatment Market Analysis and Forecast, by Region
8.1. Key Findings
8.2. Market Value Forecast, by Region
8.2.1. North America
8.2.2. Europe
8.2.3. Asia Pacific
8.2.4. Latin America
8.2.5. Middle East & Africa
8.3. Market Attractiveness, by Region
9. North America Glioma Treatment Market Analysis and Forecast
9.1. Introduction
9.1.1. Key Findings
9.2. Market Value Forecast, by Type, 2017‒2031
9.2.1. Low-Grade
9.2.1.1. grade I
9.2.1.2. grade II
9.2.2. High-grade
9.2.2.1. grade III
9.2.2.2. grade IV
9.3. Market Value Forecast, by Treatment, 2017‒2031
9.3.1. Surgery
9.3.2. Radiation Therapy
9.3.3. Chemotherapy
9.3.4. Targeted Drug Therapy
9.3.5. Others
9.4. Market Value Forecast, by Country, 2017‒2031
9.4.1. U.S.
9.4.2. Canada
9.5. Market Attractiveness Analysis
9.5.1. By Type
9.5.2. By Treatment
9.5.3. By Country
10. Europe Glioma Treatment Market Analysis and Forecast
10.1. Introduction
10.1.1. Key Findings
10.2. Market Value Forecast, by Type, 2017‒2031
10.2.1. Low-Grade
10.2.1.1. grade I
10.2.1.2. grade II
10.2.2. High-grade
10.2.2.1. grade III
10.2.2.2. grade IV
10.3. Market Value Forecast, by Treatment, 2017‒2031
10.3.1. Surgery
10.3.2. Radiation Therapy
10.3.3. Chemotherapy
10.3.4. Targeted Drug Therapy
10.3.5. Others
10.4. Market Value Forecast, by Country/Sub-region, 2017‒2031
10.4.1. Germany
10.4.2. U.K.
10.4.3. France
10.4.4. Italy
10.4.5. Spain
10.4.6. Rest of Europe
10.5. Market Attractiveness Analysis
10.5.1. By Type
10.5.2. By Treatment
10.5.3. By Country/Sub-region
11. Asia Pacific Glioma Treatment Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.2. Market Value Forecast, by Type, 2017‒2031
11.2.1. Low-Grade
11.2.1.1. grade I
11.2.1.2. grade II
11.2.2. High-grade
11.2.2.1. grade III
11.2.2.2. grade IV
11.3. Market Value Forecast, by Treatment, 2017‒2031
11.3.1. Surgery
11.3.2. Radiation Therapy
11.3.3. Chemotherapy
11.3.4. Targeted Drug Therapy
11.3.5. Others
11.4. Market Value Forecast, by Country/Sub-region, 2017‒2031
11.4.1. China
11.4.2. Japan
11.4.3. India
11.4.4. Australia & New Zealand
11.4.5. Rest of Asia Pacific
11.5. Market Attractiveness Analysis
11.5.1. By Type
11.5.2. By Treatment
11.5.3. By Country/Sub-region
12. Latin America Glioma Treatment Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Market Value Forecast, by Type, 2017‒2031
12.2.1. Low-Grade
12.2.1.1. grade I
12.2.1.2. grade II
12.2.2. High-grade
12.2.2.1. grade III
12.2.2.2. grade IV
12.3. Market Value Forecast, by Treatment, 2017‒2031
12.3.1. Surgery
12.3.2. Radiation Therapy
12.3.3. Chemotherapy
12.3.4. Targeted Drug Therapy
12.3.5. Others
12.4. Market Value Forecast, by Country/Sub-region, 2017‒2031
12.4.1. Brazil
12.4.2. Mexico
12.4.3. Rest of Latin America
12.5. Market Attractiveness Analysis
12.5.1. By Type
12.5.2. By Treatment
12.5.3. By Country/Sub-region
13. Middle East & Africa Glioma Treatment Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Market Value Forecast, by Type, 2017‒2031
13.2.1. Low-Grade
13.2.1.1. grade I
13.2.1.2. grade II
13.2.2. High-grade
13.2.2.1. grade III
13.2.2.2. grade IV
13.3. Market Value Forecast, by Treatment, 2017‒2031
13.3.1. Surgery
13.3.2. Radiation Therapy
13.3.3. Chemotherapy
13.3.4. Targeted Drug Therapy
13.3.5. Others
13.4. Market Value Forecast, by Country/Sub-region, 2017‒2031
13.4.1. GCC Countries
13.4.2. South Africa
13.4.3. Rest of Middle East & Africa
13.5. Market Attractiveness Analysis
13.5.1. By Type
13.5.2. By Treatment
13.5.3. By Country/Sub-region
14. Competition Landscape
14.1. Market Player – Competition Matrix (By Tier and Size of companies)
14.2. Market Share Analysis By Company (2021)
14.3. Company Profiles
14.3.1. Bristol-Myers Squibb Company
14.3.1.1. Company Overview
14.3.1.2. Company Financials
14.3.1.3. Growth Strategies
14.3.1.4. SWOT Analysis
14.3.2. Genentech, Inc. (F. Hoffmann-La Roche Ltd.
14.3.2.1. Company Overview
14.3.2.2. Company Financials
14.3.2.3. Growth Strategies
14.3.2.4. SWOT Analysis
14.3.3. Pfizer, Inc.
14.3.3.1. Company Overview
14.3.3.2. Company Financials
14.3.3.3. Growth Strategies
14.3.3.4. SWOT Analysis
14.3.4. Merck & Co., Inc
14.3.4.1. Company Overview
14.3.4.2. Company Financials
14.3.4.3. Growth Strategies
14.3.4.4. SWOT Analysis
14.3.5. Teva Pharmaceutical Industries Ltd
14.3.5.1. Company Overview
14.3.5.2. Company Financials
14.3.5.3. Growth Strategies
14.3.5.4. SWOT Analysis
14.3.6. Sun Pharmaceutical Industries Ltd.
14.3.6.1. Company Overview
14.3.6.2. Company Financials
14.3.6.3. Growth Strategies
14.3.6.4. SWOT Analysis
14.3.7. Amgen, Inc.
14.3.7.1. Company Overview
14.3.7.2. Company Financials
14.3.7.3. Growth Strategies
14.3.7.4. SWOT Analysis
14.3.8. Other prominent players
14.3.8.1. Company Overview
14.3.8.2. Company Financials
14.3.8.3. Growth Strategies
14.3.8.4. SWOT Analysis
Table 01: Global Glioma Treatment Market Value (US$ Mn) Forecasts, by Type, 2017–2031
Table 02: Global Glioma Treatment Market Value (US$ Mn) Forecast, by High-grade, 2017–2031
Table 03: Global Glioma Treatment Market Value (US$ Mn) Forecast, by Low-grade , 2017–2031
Table 04: Global Glioma Treatment Market Value (US$ Mn) Forecast, by Treatment, 2017–2031
Table 05: Global Glioma Treatment Market Value (US$ Mn) Forecast, by Region, 2017–2031
Table 06: North America Glioma Treatment Market Value (US$ Mn) Forecast, by Country, 2017–2031
Table 07: North America Glioma Treatment Market Value (US$ Mn) Forecast, by Type, 2017–2031
Table 08: North America Glioma Treatment Market Value (US$ Mn) Forecast, by High-grade, 2017–2031
Table 09: North America Glioma Treatment Market Value (US$ Mn) Forecast, by Low-grade, 2017–2031
Table 10: North America Glioma Treatment Market Value (US$ Mn) Forecast, by Treatment, 2017–2031
Table 11: Europe Glioma Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 12: Europe Glioma Treatment Market Value (US$ Mn) Forecast, by Type, 2017–2031
Table 13: Europe Glioma Treatment Market Value (US$ Mn) Forecast, by High-grade, 2017–2031
Table 14: Europe Glioma Treatment Market Value (US$ Mn) Forecast, by Low-grade, 2017–2031
Table 15: Europe Glioma Treatment Market Value (US$ Mn) Forecast, by Treatment, 2017–2031
Table 16: Asia Pacific Glioma Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 17: Asia Pacific Glioma Treatment Market Value (US$ Mn) Forecast, by Type, 2017–2031
Table 18: Asia Pacific Glioma Treatment Market Analysis and Value (US$ Mn) Forecast, by High-grade, 2017–2031
Table 19: Asia Pacific Glioma Treatment Market Value (US$ Mn) Forecast, by Low-grade, 2017–2031
Table 20: Asia Pacific Glioma Treatment Market Value (US$ Mn) Forecast, by Treatment, 2017–2031
Table 21: Latin America Glioma Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 22: Latin America Glioma Treatment Market Value (US$ Mn) Forecast, by Type, 2017–2031
Table 23: Latin America Glioma Treatment Market and Value (US$ Mn) Forecast, by High-grade, 2017–2031
Table 24: Latin-America Glioma Treatment Market Value (US$ Mn) Forecast, by Low-grade , 2017–2031
Table 25: Latin America Glioma Treatment Market Value (US$ Mn) Forecast, by Treatment, 2017–2031
Table 26: Middle East & Africa Glioma Treatment Market Analysis and Forecast, by Country/Sub-region, 2017–2031
Table 27: Middle East & Africa Glioma Treatment Market Analysis and Forecast, by Type, 2017–2031
Table 28: Middle East & Africa Glioma Treatment Market Analysis and Forecast, by High-grade, 2017–2031
Table 29: Middle East & Africa Glioma Treatment Market Analysis and Forecast, by Low-grade, 2017–2031
Table 30: Middle East & Africa Glioma Treatment Market Analysis and Forecast, by Treatment, 2017–2031